FY2025 · ended Dec 31, 2025 · Revenue $3.48M, -67.4% YoY · Filed Mar 23, 2026
Surrozen, Inc./DE (SRZN) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.5 million and a net loss of $242.0 million. Free cash flow was -$30.4 million. As of Jun 30, 2026 it held $102.0 million in cash and investments and $6.3 million in total debt.
Revenue (TTM)
$11.51M
Net income (TTM)
$-332.13M
-1889.2% vs year-ago TTM
Operating cash flow (TTM)
$-34.76M
-86.3% vs year-ago TTM
Free cash flow (TTM)
$-34.98M
-86.8% vs year-ago TTM
EPS (TTM)
$-128.54
-2222.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
11.49M
+250.1% vs prior year
Net cash
$95.72M
as of Jun 30, 2026
Operating margin
-385.3%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SRZN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1824893
- Former names
- Consonance-HFW Acquisition Corp. (until Aug 11, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $10.7M | $0 | $12.5M | — |
| Operating income | -$42.1M | -$25.5M | -$45.8M | -$44.3M | -$54.4M |
| Net income | -$242.0M | -$63.6M | -$43.0M | -$36.0M | -$54.6M |
| Diluted EPS | -$32.37 | -$21.67 | -$21.33 | -$15.56 | — |
| Operating cash flow | -$30.2M | -$17.6M | -$40.4M | -$44.1M | -$48.8M |
| Free cash flow | -$30.4M | -$17.7M | -$40.8M | -$44.9M | -$50.1M |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M | $137.2M |
| Total liabilities | $286.5M | $69.8M | $8.1M | $13.4M | $27.5M |
| Stockholders' equity | -$187.8M | -$21.4M | $37.9M | $76.0M | $109.7M |
| Cash and investments | $89.2M | $34.6M | $36.0M | $75.8M | $123.5M |
| Total debt | $6.6M | $8.5M | $3.4M | $5.6M | $7.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Unregistered share sale
|
Oct 20, 2026 | Oct 20, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 14, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
All 496 Surrozen, Inc./DE SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.